🇺🇸 FDA
Patent

US 9107887

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

granted A61KA61K2039/505A61K31/352

Quick answer

US patent 9107887 (Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer) held by Provectus Pharmaceuticals, Inc. expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Provectus Pharmaceuticals, Inc.
Grant date
Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K31/352, A61K31/365, A61K38/193